BioSpace News Archive

Amyris, Inc. (Nasdaq:AMRS), a leading synthetic biotechnology company with leadership in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, announces that its first health and nutrition ingredient received a validation by a unanimous Panel of Medical Experts as Gene

A recently published “Pilot Study” in the Annals of Plastic and Reconstructive Surgery by Gregory Chernoff, M.D., F.R.C.S.(C) of Chernoff Plastic Surgery located in Indianapolis, Indiana http://www.remedypublications.com/open-access/the-utilization-of-a-topical-nitric-oxide-generating-serum-in-5842.pdf concentrated on the use of Nitric Oxide in the aging skin population.

Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. First Qua

Optical filters designed for real-time qPCR applications / COVID-19 testing can be ordered online now.

CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data from two ongoing Phase 1/2 clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies have been accepted for an oral presentation at the EHA Congress, which will take place virtually from June 11-14, 2020.

OncoSec launches broader #TogetherAgainstCancer campaign and is proud to partner with melanoma advocacy partners throughout the month of May [14-May-2020] PENNINGTON, N.J. and SAN DIEGO , May 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today that its partnering w

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-altered cancers and avapritinib in systemic mastocytosis.

Citius Pharmaceuticals , Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 7,058,824 shares of its common stock, at a purchase pr

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology today reports its Q1 2020 financial results and provides a business update.

Menarini Ricerche announces the completion of the dose escalation part of the First in Human, phase I/II DIAMOND trial currently ongoing to evaluate SEL24/MEN1703, a first in class, oral dual PIM/FLT3 inhibitor in development for the treatment of acute myeloid leukemia.